Sirnaomics Ltd. (FRA:V5Z)

Market Cap	56.01M +33.7%
Revenue (ttm)	n/a
Net Income	-12.27M
EPS	-0.13
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4860
Previous Close	0.4920
Day's Range	0.4800 - 0.4860
52-Week Range	0.4320 - 2.3400
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Sirnaomics

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs in the People’s Republic of China. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates comprising STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; STP369 to treat head and neck cancer; and STP707 and STP355 to treat solid tumo...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 37
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: V5Z

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error